Expanding our therapeutic options: Beta blockers for breast cancer?

Journal of Clinical Oncology

Volumn 29, Issue 19, 2011, Pages 2612-2616

  Ganz, Patricia A ^a   Cole, Steven W ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; INTERLEUKIN 6; METFORMIN; METOPROLOL; PROPRANOLOL; TAMOXIFEN; TRASTUZUMAB;

ADJUVANT CHEMOTHERAPY; AMENORRHEA; BREAST CANCER; CANCER SURVIVAL; DIABETES MELLITUS; DISEASE FREE SURVIVAL; DISTANT METASTASIS; EDITORIAL; HUMAN; HYPERTENSION; NONHUMAN; OBESITY; OVERALL SURVIVAL; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; TUMOR MICROENVIRONMENT; WEIGHT GAIN;

ADRENERGIC BETA-ANTAGONISTS; ATENOLOL; BREAST NEOPLASMS; DIABETES COMPLICATIONS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; HYPERTENSION; MEDICAL ONCOLOGY; MODELS, BIOLOGICAL; NEOPLASM METASTASIS; PROPRANOLOL; RECEPTORS, ESTROGEN; RECURRENCE; TREATMENT OUTCOME;

EID: 79960133993     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.35.8820     Document Type: Editorial

References (44)

1. Early Breast Cancer Trialists' Collaborative Group: Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet 365:1687-1717, 2005
2. Berry DA, Cirrincione C, Henderson IC, et al: Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA 295:1658-1667, 2006
3. Swain SM, Jeong JH, Geyer CE, Jr., et al: Longer therapy, iatrogenic amenorrhea, and survival in early breast cancer. N Engl J Med 362: 2053-2065, 2010
4. Swain SM, Jeong JH, Wolmark N: Amenorrhea from breast cancer therapy is not a matter of dose. N Engl J Med 363:2268-2270, 2010
5. Yarden Y: The biological framework: Translational research from bench to clinic. The Oncologist 15:1-7, 2010
6. Chiang AC, Massague J: Molecular basis of metastasis. N Engl J Med 359:2814-2823, 2008
7. McAllister SS, Weinberg RA: Tumor-host interactions: A far-reaching relationship. J Clin Oncol 28:4022-4028, 2010
8. Terry MB, Gammon MD, Zhang FF, et al: Association of frequency and duration of aspirin use and hormone receptor status with breast cancer risk. JAMA 291:2433-2440, 2004 (Pubitemid 38669186)
9. DuBois RN: Aspirin and breast cancer prevention. JAMA 291:2488-2489, 2004
10. Sinicrope FA, Dannenberg AJ: Obesity and breast cancer prognosis: Weight of the evidence. J Clin Oncol 29:4-7, 2011
11. Subbaramaiah K, Howe LR, Bhardwaj P, et al: Obesity is associated with inflammation and elevated aromatase expression in the mouse mammary gland. Cancer Prevention Research 4:329-346, 2011
12. Goodwin PJ, Meyerhardt JA, Hursting SD: Host factors and cancer outcome. J Clin Oncol 28:4019-4021, 2010
13. Antoni MH, Lutgendorf SK, Cole SW, et al: The influence of bio-behavioural factors on tumour biology: Pathways and mechanisms. Nat Rev Cancer 6:240-248, 2006 (Pubitemid 43292567)
14. Barron TI, Connolly RM, Sharp L, et al: Beta blockers and breast cancer mortality: A population-based study. J Clin Oncol 29:2635-2644, 2011
15. Melhem-Bertrandt A, Chavez-MacGregor M, Lei X, et al: Beta-blocker use is associated with improved relapse-free survival in patients with triple-negative breast cancer. J Clin Oncol doi: 29:2645-2652, 2011
16. Thaker PH, Han LY, Kamat AA, et al: Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma. Nat Med 12:939-944, 2006 (Pubitemid 44175146)
17. Sloan EK, Priceman SJ, Cox BF, et al: The sympathetic nervous system induces a metastatic switch in primary breast cancer. Cancer Res 70:7042-7052, 2010
18. Powe DG, Voss MJ, Zänker KS et al: Beta-blocker drug therapy reduces secondary cancer formation in breast cancer and improves cancer specific survival. Oncotarget 1:628-638, 2010
19. Algazi M, Plu-Bureau G, Flahault A, et al: Could treatments with betablockers be associated with a reduction in cancer risk? Rev Epidemiol Sante Publique 52:53-65, 2004
20. Perron L, Bairati I, Harel F, Meyer F: Antihypertensive drug use and the risk of prostate cancer (Canada). Cancer Causes Control 15:535-541, 2004 (Pubitemid 39070071)
21. Schuller HM: Beta-adrenergic signaling: A novel target for cancer therapy? Oncotarget 1:466-469, 2010
22. Jiralerspong S, Palla SL, Giordano SH, et al: Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. J Clin Oncol 27:3297-3302, 2009
23. Smith C, Teitler M: Beta-blocker selectivity at cloned human beta1- and beta2-adrenergic receptors. Cardiovasc Drugs Ther 13:123-126, 1999 (Pubitemid 29224837)
24. Drell IV TL, Joseph J, Lang K, et al: Effects of neurotransmitters on the chemokinesis and chemotaxis of MDA-MB-468 human breast carcinoma cells. Breast Cancer Res Treat 80:63-70, 2003 (Pubitemid 36851285)
25. Lang K, Drell TL, Lindecke A, et al: Induction of a metastatogenic tumor cell type by neurotransmitters and its pharmacological inhibition by established drugs. Int J Cancer 112:231-238, 2004 (Pubitemid 39244363)
26. Powe D, Voss M, Habashy H, et al: Alpha- and beta-adrenergic receptor (AR) protein expression is associated with poor clinical outcome in breast cancer: An immunohistochemical study. Breast Cancer Res Treat 1-7, 2011
27. Draoui AB, Vandewalle B, Hornez L, et al: Beta-adrenergic receptors in human breast cancer: Identification, characterization and correlation with progesterone and estradiol receptors. Anticancer Res 11:667-680, 1991
28. Madden K, Szpunar M, Brown E: β-Adrenergic receptors (β-AR) regulate VEGF and IL-6 production by divergent pathways in high β-AR-expressing breast cancer cell lines. Breast Cancer Res Treat [Epub ahead of print on January 14, 2011]
29. Hanahan D, Weinberg R: Hallmarks of cancer: The next generation. Cell 144:646-674, 2011
30. Shi M, Liu D, Duan H, et al: The beta2-adrenergic receptor and Her2 comprise a positive feedback loop in human breast cancer cells. Breast Cancer Res Treat 125:351-362, 2011
31. Sastry KSR, Karpova Y, Prokopovich S, et al: Epinephrine protects cancer cells from apoptosis via activation of cAMP-dependent protein kinase and BAD phosphorylation. J Biol Chem 282:14094-14100, 2007 (Pubitemid 47100469)
32. Sood AK, Armaiz-Pena GN, Halder J, et al: Adrenergic modulation of focal adhesion kinase protects human ovarian cancer cells from anoikis. J Clin Invest 120:1515-1523, 2010
33. Gu L, Lau SK, Loera S, et al: Protein kinase A activation confers resistance to trastuzumab in human breast cancer cell lines. Clin Cancer Res 15:7196-7206, 2009
34. Pierce BL, Ballard-Barbash R, Bernstein L, et al: Elevated biomarkers of inflammation are associated with reduced survival among breast cancer patients. J Clin Oncol 27:3437-3444, 2009
35. Ahmed OI, Adel AM, Diab DR, et al: Prognostic value of serum level of interleukin-6 and interleukin-8 in metastatic breast cancer patients. Egypt J Immunol 13:61-68, 2006
36. Salgado R, Junius S, Benoy I, et al: Circulating interleukin-6 predicts survival in patients with metastatic breast cancer. Int J Cancer 103:642-646, 2003 (Pubitemid 36091468)
37. Zhang GJ, Adachi I: Serum interleukin-6 levels correlate to tumor progression and prognosis in metastatic breast carcinoma. Anticancer Res 19:1432, 1999
38. Siemes C, Visser LE, Coebergh JW, et al: C-reactive protein levels, variation in the C-reactive protein gene, and cancer risk: The Rotterdam Study. J Clin Oncol 24:5216-5222, 2006 (Pubitemid 46631365)
39. Knupfer H, Preiss R: Significance of interleukin-6 (IL-6) in breast cancer (review). Breast Cancer Res Treat 102:129-135, 2007
40. Bachelot T, Ray-Coquard I, Menetrier-Caux C, et al: Prognostic value of serum levels of interleukin 6 and of serum and plasma levels of vascular endothelial growth factor in hormone-refractory metastatic breast cancer patients. Br J Cancer 88:1721-1726, 2003 (Pubitemid 36760416)
41. Cole SW, Arevalo JMG, Takahashi R, et al: Computational identification of gene social environment interaction at the human IL6 locus. Proc Natl Acad Sci U S A 107:5681-5686, 2010
42. DeMichele A, Gray R, Horn M, et al: Host genetic variants in the interleukin-6 promoter predict poor outcome in patients with estrogen receptor-positive, node-positive breast cancer. Cancer Res 69:4184-4191, 2009
43. DeMichele A, Martin AM, Mick R, et al: Interleukin-6-174G→C polymorphism is associated with improved outcome in high-risk breast cancer. Cancer Res 63:8051-8056, 2003 (Pubitemid 37466744)
44. Snoussi K, Strosberg AD, Bouaouina N, et al: Genetic variation in proinflammatory cytokines (interleukin-1beta, interleukin-1alpha and interleukin-6) associated with the aggressive forms, survival, and relapse prediction of breast carcinoma. Eur Cytokine Netw 16:253-260, 2005 (Pubitemid 350056539)